| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2026 ( Subtotal = $234,892,491 ) (Continued on the next page) |
| | 2026 | 2026 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R01CA300233 | The PERSON intervention: Using Patient portals to Elicit essential patient-Reported elements of communication with clinicians Supporting person-centered ONcologic care | 000 | 1 | NIH | 6/30/2026 | $745,458 |
| | 2026 | 2026 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R01CA315216 | Improve precision medicine for renal cell carcinoma patients of African ancestry through computational and functional genomics | 000 | 1 | NIH | 8/10/2026 | $690,977 |
| | 2026 | 2026 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | UH3CA290241 | CD28-KITv CAR T cells with PD-1 dominant negative receptor | 001 | 3 | NIH | 9/14/2026 | $407,794 |
| | 2026 | 2026 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | F32GM167147 | Histone Acetylation and Chromatin Remodeling as Epigenetic Drivers of Meiotic Recombination | 001 | 1 | NIH | 8/24/2026 | $0 |
| | 2026 | 2026 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | F32GM167147 | Histone Acetylation and Chromatin Remodeling as Epigenetic Drivers of Meiotic Recombination | 000 | 1 | NIH | 8/24/2026 | $79,230 |
| | 2026 | 2026 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R01CA312225 | CD4 T cells and immune cell triads in anti-tumor immunity | 000 | 1 | NIH | 6/30/2026 | $671,252 |
| | 2026 | 2026 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R21CA301202 | Innate & Adaptive Determinants of Post-CAR Cytokine Release Syndrome | 000 | 1 | NIH | 3/31/2026 | $452,540 |
| | 2026 | 2026 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R01AG102339 | Restoring Drug Responsiveness in Alzheimer’s Disease by Repairing Target Architecture | 000 | 1 | NIH | 8/25/2026 | $1,212,742 |
| | 2026 | 2026 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | K08CA296467 | Interrogating the Role of p53 Mutation Class on Ovarian Cancer Evolution | 000 | 1 | NIH | 8/21/2026 | $294,452 |
| | 2026 | 2026 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R01CA308278 | Overcoming chronic inflammation-driven T cell quiescence in gastric adenocarcinoma | 000 | 1 | NIH | 4/6/2026 | $730,097 |
| | 2026 | 2026 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | K08AI201873 | T Cell Precursor-Induced Immune Reprogramming After Hematopoietic Stem Cell Transplantation | 000 | 1 | NIH | 8/18/2026 | $194,616 |
| | 2026 | 2026 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | F32DK149569 | Next Generation Hyperpolarized Magnetic Resonance Imaging with [U-2H, 3-13C]Fructose for Staging Diet-Induced Liver Disease | 000 | 1 | NIH | 9/14/2026 | $76,300 |
| | 2026 | 2026 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R01AI196092 | Decoding the role of Aire-expressing Thetis cells in peripheral self-tolerance | 000 | 1 | NIH | 2/3/2026 | $616,042 |
| | 2026 | 2026 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R01AI196228 | Chalkophore mediated respiratory oxidase flexibility and M. tuberculosis virulence | 000 | 1 | NIH | 1/28/2026 | $3,178,476 |
| | 2026 | 2026 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R03CA303915 | QuitTrack: Adaptation and Evaluation of a Community Navigator-Led Tobacco Cessation Intervention for Cancer Patients Experiencing Food Insecurity | 000 | 1 | NIH | 7/27/2026 | $177,500 |
| | 2026 | 2026 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R21CA309323 | RECONJOINT: A Preference Elicitation Tool to Improve Shared Decision Making for Breast Reconstruction Surgery | 000 | 1 | NIH | 6/11/2026 | $457,252 |
| | 2026 | 2026 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R01DE035884 | Salivary Neural Development Programs Enable Adenoid Cystic Carcinoma Progression | 000 | 1 | NIH | 7/22/2026 | $769,938 |
| | 2026 | 2026 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | K08CA308856 | Targeting Alternative Lengthening of Telomeres in Cancer | 000 | 1 | NIH | 7/20/2026 | $263,073 |
| | 2026 | 2026 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R01CA312279 | Repurposing HSP90 inhibitors as a new RTK condensate-directed therapy in cancer | 000 | 1 | NIH | 7/27/2026 | $577,331 |
| | 2026 | 2026 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | F32AI202787 | Ecological and molecular mechanisms linking β-lactam exposure to Enterococcus faecium strain dynamics and bloodstream infection risk | 000 | 1 | NIH | 7/30/2026 | $76,300 |
| | 2026 | 2026 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | K08CA301096 | The evolutionary landscape of BRCA-associated breast cancer and its impact on endocrine therapy resistance | 000 | 1 | NIH | 6/16/2026 | $246,362 |
| | 2026 | 2026 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | K99CA312787 | Targeting androgen receptor with non-steroidal next-generation radiopharmaceuticals | 000 | 1 | NIH | 7/29/2026 | $153,330 |
| | 2026 | 2026 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R01CA313953 | Short-wave infrared Cerenkov imaging to better visualize targeted radiotherapy and diagnostic radiotracers | 000 | 1 | NIH | 6/19/2026 | $644,423 |
| | 2026 | 2026 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R01CA312002 | Decoding basal multipotency for histological transformation in lung cancer patients | 000 | 1 | NIH | 7/30/2026 | $752,280 |
| | 2026 | 2026 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | K08HL183856 | The Role of Zbtb1 in Normal and Clonal Hematopoiesis | 000 | 1 | NIH | 8/4/2026 | $169,020 |
| | 2026 | 2026 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R01CA305504 | P-Selectin-Targeting Nanoparticles to Potentiate Cancer Immunotherapy | 000 | 1 | NIH | 8/28/2026 | $709,145 |
| | 2026 | 2026 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | K99CA315558 | Targeting Senescence- and Fibrosis-Associated Tumor States via Engineered Immunity | 000 | 1 | NIH | 7/24/2026 | $146,299 |
| | 2026 | 2026 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R01CA298818 | Modulating the tumor microenvironment to enhance nanoparticle delivery | 000 | 1 | NIH | 8/25/2026 | $699,794 |
| | 2026 | 2026 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | F31AI191721 | Role of Arid1a in NK cell development and antiviral immunity | 002 | 1 | NIH | 4/7/2026 | $0 |
| | 2026 | 2026 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | F31AI191721 | Role of Arid1a in NK cell development and antiviral immunity | 001 | 1 | NIH | 4/7/2026 | $46,564 |
| | 2026 | 2026 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | F31AI191721 | Role of Arid1a in NK cell development and antiviral immunity | 001 | 1 | NIH | 4/7/2026 | -$46,564 |
| | 2026 | 2026 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | F31AI191721 | Role of Arid1a in NK cell development and antiviral immunity | 000 | 1 | NIH | 4/3/2026 | $46,564 |
| | 2026 | 2026 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R01CA304551 | MIRDsoft radiation dosimetry | 000 | 1 | NIH | 6/10/2026 | $676,849 |
| | 2026 | 2026 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R21OH013130 | Genomic Characterization and Clinical Outcomes of Cancers in WTC-Exposed Survivors & Responders | 00 | 1 | CDC | 8/27/2026 | $287,197 |
| | 2026 | 2026 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R37CA259177 | Molecular mechanisms of T cell responses to a clonal neoantigen resulting from a mutated driver oncogene. | 000 | 6 | NIH | 4/6/2026 | $538,178 |
| | 2026 | 2026 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R01CA315819 | Digital Physical Activity in Individuals Living with Metastatic Cancer | 000 | 1 | NIH | 9/14/2026 | $751,614 |
| | 2026 | 2026 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R01FD008219 | A retrospective and prospective study of leiomyosarcoma systemic therapy outcomes informed by tumor genomics | 000 | 1 | FDA | 9/23/2026 | $345,343 |
| | 2026 | 2026 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R01FD008780 | Intraperitoneal CAR T-cell therapy for peritoneal mesothelioma | 000 | 1 | FDA | 9/23/2026 | $650,000 |
| | 2026 | 2026 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | DP2EB041714 | Decoding Cell-Fate Decisions Through Molecular Recording | 000 | 1 | NIH | 9/3/2026 | $843,125 |
| | 2026 | 2026 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | K08CA313764 | Adaptation of an Evidence-Based Goals of Care Communication Intervention for Adolescent and Young Adult Cancer Patients | 000 | 1 | NIH | 9/3/2026 | $252,023 |
| | 2026 | 2026 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R01CA315610 | A Pragmatic Randomized Controlled Trial of Brief Meaning Centered Psychotherapy for Patients with Advanced Cancer Receiving Homecare | 000 | 1 | NIH | 9/11/2026 | $757,740 |
| | 2026 | 2026 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | K08CA312653 | Transforming the Peripartum Period from a Breast Cancer Screening “Blind Spot” into a Window for Enhanced Cancer Detection | 000 | 1 | NIH | 9/3/2026 | $294,080 |
| | 2026 | 2026 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R01FD008542 | A Phase 2 Trial of Darolutamide plus Leuprolide Acetate in Advanced Androgen Receptor Positive Salivary Gland Cancer | 000 | 1 | FDA | 9/28/2026 | $250,000 |
| | 2026 | 2026 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R01CA316662 | Drivers of Lineage Reprogramming in Malignant Transformation of Diffuse Gastric Cancer | 000 | 1 | NIH | 9/3/2026 | $736,625 |
| | 2026 | 2026 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R01FD008542 | A Phase 2 Trial of Darolutamide plus Leuprolide Acetate in Advanced Androgen Receptor Positive Salivary Gland Cancer | 000 | 1 | FDA | 9/28/2026 | $300,000 |
| | 2026 | 2026 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R01FD008542 | A Phase 2 Trial of Darolutamide plus Leuprolide Acetate in Advanced Androgen Receptor Positive Salivary Gland Cancer | 000 | 1 | FDA | 9/28/2026 | $1,133,632 |
| | 2026 | 2026 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R01FD008542 | A Phase 2 Trial of Darolutamide plus Leuprolide Acetate in Advanced Androgen Receptor Positive Salivary Gland Cancer | 000 | 1 | FDA | 9/28/2026 | $250,000 |
| | 2026 | 2026 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R01FD008542 | A Phase 2 Trial of Darolutamide plus Leuprolide Acetate in Advanced Androgen Receptor Positive Salivary Gland Cancer | 000 | 1 | FDA | 9/28/2026 | $650,000 |
| | 2026 | 2026 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R01CA309345 | HER2 PET imaging to assess HER2 heterogeneity and predict response to HER2-targeted therapy in biliary tract cancer | 000 | 1 | NIH | 3/19/2026 | $715,002 |
|
